Price Chart

Profile

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
URL https://www.oragenics.com
Investor Relations URL http://www.oragenics.com/?q=investors
HQ State/Province Florida
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 08, 2025 (est.)
Last Earnings Release May. 09, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
URL https://www.oragenics.com
Investor Relations URL http://www.oragenics.com/?q=investors
HQ State/Province Florida
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 08, 2025 (est.)
Last Earnings Release May. 09, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A